BiotechTube
Home/Dyne Therapeutics/Joshua T. Brumm
JT

Joshua T. Brumm

President, Chief Executive Officer, and Director

Dyne Therapeutics

Therapeutic Areas

Neuromuscular DiseasesRare DiseasesGenetic Disorders

Dyne Therapeutics Pipeline

DrugIndicationPhase
DYNE-101Myotonic Dystrophy Type 1 (DM1)Phase 1/2
DYNE-251Duchenne Muscular Dystrophy (DMD) amenable to exon 51 skippingPhase 1/2
DYNE-301Facioscapulohumeral Muscular Dystrophy (FSHD)Phase 1/2

Leadership Team at Dyne Therapeutics

SG
Susanna G. High
Chief Operating Officer
OB
Oxana B. Corjuc, CPA
Chief Financial Officer
JT
John T. McHutchison, AO, MD
Chief Medical Officer
CR
Carlo Rizzuto, PhD
Chief Scientific Officer
JK
Jennifer K. Yates, J.D.
Chief Legal Officer and Corporate Secretary
WR
Wildon R. Farwell, MD, MPH
Chief Development Officer
JP
Jason P. Rhodes
Chairman of the Board
CA
Catherine A. Sohn, PharmD
Director
LM
Lawrence M. Alleva
Director
ML
Michelle L. Griffin
Director
View full Dyne Therapeutics profile